据上海证券报报道，某隔膜行业一梯队企业宣布对其湿法隔膜产品售价进行调整，上调幅度达30%。鑫 椤锂电表示，预计本轮锂电隔膜整体涨价幅度可达20%以上，有望带动隔膜企业业绩由亏损或盈亏打平 转为盈利。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 公司方面，据上市公司互动平台表示， 美联新材：公司控股子公司安徽美芯的湿法隔膜销量同比增长了4倍。 长阳科技：公司可用于固态或半固态电池用湿法隔膜已取得该行业头部客户小批量订单以及腰部客户的 企业订单。 行业分析认为，湿法隔膜行业一梯队和二梯队的湿法隔膜厂商产能利用率均保持满产状态，湿法隔膜行 业整体产能利用率已经达到90%以上水平，原因是一方面受到四季度终端需求旺盛的影响，另外在持续 涨价的背景下，下游厂商也适当进行原料备货以应对明年的需求。同时，2026年下游电池厂有望进一 步"干法转湿法"，进一步拉动湿法隔膜的需求，随着年底上下游针对2026年的供应进行年底商议，"大 概率将会出现电池厂的大额保供订单"。 供给方面，招商证券认为，此前行业盈利能力处于历史低位，2025二三季度恩捷、星源出现亏损。同 时，主要参与者带息负债率水平 ...

Core Insights - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for HLX37 injection [1] - The Phase I clinical trial for HLX37 is planned to be conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - HLX37 is a recombinant humanized bispecific antibody targeting PD-L1 and VEGF, intended for the treatment of advanced/metastatic solid tumors [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HLX37 injection for treating advanced/metastatic solid tumor patients [1] Group 1: Clinical Trial Approval - The approval allows for the initiation of Phase I clinical trials for HLX37 in mainland China once conditions are met [1] - The clinical trial is aimed at patients with advanced or metastatic solid tumors [1] Group 2: Research and Development Investment - As of October 2025, the cumulative R&D investment for HLX37 by the group is approximately RMB 50.23 million (unaudited) [1]

Group 1 - The main point of the article highlights the net inflow of main funds in the Shanghai and Shenzhen markets, amounting to 10.84 billion yuan, with the Sci-Tech Innovation Board seeing a net inflow of 320 million yuan [1] - A total of 250 stocks experienced net inflows, while 339 stocks saw net outflows, indicating a mixed sentiment in the market [1] - Among the stocks with significant net inflows, Jinghe Integrated led with a net inflow of 183 million yuan, followed by Wanrun New Energy and Jinpan Technology with inflows of 144 million yuan and 139 million yuan respectively [2] Group 2 - There are 52 stocks that have seen continuous net inflows for more than three trading days, with Sunshine Nuohe leading at eight consecutive days of inflow [2] - Conversely, 127 stocks have experienced continuous net outflows, with Zhimingda showing the longest streak at 19 consecutive days of outflow [2] - The top stocks by net inflow include Jinghe Integrated, Wanrun New Energy, and Jinpan Technology, with respective inflow rates of 8.41%, 10.21%, and 6.80% [2][3]

Group 1: Industry Overview - The lithium battery separator industry shows signs of recovery in the first three quarters of 2025, with over 50% of listed companies reporting positive revenue growth year-on-year [3][4] - Major players like Enjie and Xingyuan Materials reported revenue growth of 27.85% and 13.53% respectively [4][6] - The overall net profit of the lithium battery separator industry is on the rise, contrasting with the decline seen in 2024, with over half of the listed companies turning from negative to positive net profit [6][8] Group 2: Company Performance Analysis Xingyuan Materials - In the first three quarters of 2025, Xingyuan Materials achieved revenue of 29.58 billion, a year-on-year increase of 13.53%, but net profit fell by 67.25% to 1.14 billion [13][11] - The company's gross margin decreased by 7.64 percentage points, while net margin dropped by 8.71 percentage points [13][9] Enjie - Enjie reported revenue of 95.43 billion in the first three quarters of 2025, marking a 27.85% increase, but net profit fell to -0.86 billion, a decline of 119.46% [16][17] - The gross margin decreased by 5.06 percentage points, and net margin fell by 7.19 percentage points [16][9] Cangzhou Mingzhu - Cangzhou Mingzhu achieved revenue of 20.78 billion, a 5.9% increase, with net profit rising slightly by 0.99% to 1.4 billion [20][21] - The gross margin increased by 1.27 percentage points, while net margin decreased by 0.32 percentage points [20][9] Zhongcai Technology - Zhongcai Technology reported revenue of 217 billion, a 29.09% increase, and net profit of 14.8 billion, a significant rise of 143.24% [25][26] - Both gross and net margins improved, with gross margin up by 1.87 percentage points and net margin up by 3.5 percentage points [25][9] Putailai - Putailai's revenue reached 108.3 billion, a 10.06% increase, with net profit growing by 37.25% to 17 billion [28][29] - The company saw improvements in both gross margin (up 3.36 percentage points) and net margin (up 2.59 percentage points) [28][9] Henglian Petrochemical - Henglian Petrochemical reported revenue of 157.5 billion, a decline of 11.46%, with net profit slightly down by 1.61% to 50.23 billion [32][31] - Despite the revenue drop, both gross and net margins increased, with gross margin up by 3.1 percentage points and net margin up by 0.31 percentage points [32][9] Meilian New Materials - Meilian New Materials experienced a revenue decline of 1.69% to 12.47 billion, with a net loss of 0.37 billion, a significant drop of 201.86% [34][35] - The company faced reductions in both gross margin (down 7.88 percentage points) and net margin (down 8.61 percentage points) [34][9] Dongfeng Co. - Dongfeng Co. reported revenue of 70.11 billion, a decrease of 12.13%, but net profit increased by 188.57% to 1.02 billion [38][39] - The company improved its gross margin by 0.48 percentage points and net margin by 2.89 percentage points [38][9] Changyang Technology - Changyang Technology's revenue fell by 19.38% to 8.09 billion, with a net loss of 0.05 billion, a decline of 128.82% [41][42] - The gross margin improved by 6.66 percentage points, while net margin decreased by 2.51 percentage points [41][9]

Core Viewpoint - The company has received orders for its solid-state and semi-solid-state battery electrolyte composite membranes from leading domestic and international clients, but the market demand is not yet significant, and the revenue generated is currently small, which will not have a major impact on the company's operating performance in the short term [1] Group 1 - The company has obtained orders for its solid-state or semi-solid-state battery electrolyte composite membranes from top and mid-tier clients in the industry [1] - The market demand for these products has not yet ramped up significantly [1] - The revenue from these products is currently small and will not significantly affect the company's operating performance in the short term [1]

Core Viewpoint - The company is focused on expanding its market share globally by enhancing its reflective functional films and exploring new application scenarios [1] Group 1: Business Strategy - The company aims to strengthen its core product lines, particularly reflective functional films, while actively seeking new application areas [1] - There is a commitment to concentrate resources and R&D efforts on optical base films, solid and semi-solid electrolyte base films, and CPI films to overcome technical barriers and achieve industrialization [1] - The company plans to develop a champion product series while ensuring comprehensive import substitution [1] Group 2: Target Applications - The company will focus on four major application scenarios: new displays, semiconductors, 5G, and new energy vehicles, as well as energy storage [1] - There is an emphasis on developing key functional film products that are heavily reliant on imports and urgently need to achieve import substitution within these four application areas [1] - The company is also committed to researching and reserving new products that align with future technological frontiers [1]

Core Viewpoint - Changyang Technology is actively developing its CPI (Transparent Polyimide Film) project and is accelerating the development and validation process of the CPI film project [1] Group 1 - The company is currently constructing its CPI project [1] - The company aims to speed up the development and validation of the CPI film project [1]

Core Viewpoint - The company is currently constructing its first CPI film production line and is accelerating the development and validation of its CPI film products [1] Group 1 - Investors inquired about the completion status of the company's first CPI film production line [1] - The company confirmed that the CPI project is under construction [1] - The company aims to speed up the development and verification process of its transparent polyimide film products [1]

Core Viewpoint - The company is committed to strengthening its position in the functional film market by expanding its product offerings and focusing on key application areas that require import substitution [1] Group 1: Market Research and Development Plans - The company continues to conduct market research on functional films to identify potential areas for development [1] - The company aims to enhance its market position by focusing on reflective functional films and exploring new application scenarios [1] Group 2: Investment in R&D - The company is concentrating its resources and R&D team on increasing investments in optical base films, solid and semi-solid electrolyte base films, and CPI films [1] - The goal is to overcome core technological barriers and achieve industrialization while creating a champion product series [1] Group 3: Focused Application Areas - The company will prioritize four major application scenarios: new displays, semiconductors, 5G, and new energy vehicles and energy storage [1] - It plans to develop critical functional film products that are heavily reliant on imports and urgently need to achieve import substitution in these areas [1]